New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Combination therapy outperforms chemotherapy in clinical trial for patients with chronic lymphocytic leukemia

Combination therapy outperforms chemotherapy in clinical trial for patients with chronic lymphocytic leukemia

by University of AmsterdamCredit: Unsplash/CC0 Public DomainChemotherapy has been the most effective treatment to date for young and fit patients with chronic lymphocytic leukemia (CLL). The dise
Oncology February 03,2024
Combination therapy outperforms chemotherapy in clinical trial for patients with chronic lymphocytic leukemia

Combination therapy outperforms chemotherapy in clinical trial for patients with chronic lymphocytic leukemia

by University of AmsterdamCredit: Unsplash/CC0 Public DomainChemotherapy has been the most effective treatment to date for young and fit patients with chronic lymphocytic leukemia (CLL). The dise
Oncology February 03,2024
Everolimus inhibits angiogenesis and lymphangiogenesis in TP53 mutant HNSCC via STAT3/HIF-1α/VEGF pathway

Everolimus inhibits angiogenesis and lymphangiogenesis in TP53 mutant HNSCC via STAT3/HIF-1α/VEGF pathway

by Impact Journals LLCEverolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.283
Oncology February 03,2024
Everolimus inhibits angiogenesis and lymphangiogenesis in TP53 mutant HNSCC via STAT3/HIF-1α/VEGF pathway

Everolimus inhibits angiogenesis and lymphangiogenesis in TP53 mutant HNSCC via STAT3/HIF-1α/VEGF pathway

by Impact Journals LLCEverolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.283
Oncology February 03,2024
Early-stage cancer diagnoses decreased sharply in the US during first year of COVID-19 pandemic

Early-stage cancer diagnoses decreased sharply in the US during first year of COVID-19 pandemic

by American Cancer SocietyCOVID-19 and Cancer. Credit: American Cancer SocietyA new study from researchers at the American Cancer Society (ACS) found monthly adult cancer diagnoses decreased by h
Oncology February 03,2024
Early-stage cancer diagnoses decreased sharply in the US during first year of COVID-19 pandemic

Early-stage cancer diagnoses decreased sharply in the US during first year of COVID-19 pandemic

by American Cancer SocietyCOVID-19 and Cancer. Credit: American Cancer SocietyA new study from researchers at the American Cancer Society (ACS) found monthly adult cancer diagnoses decreased by h
Oncology February 03,2024
Evidence supports three-year interval for multi-target stool DNA screening for those at average risk of colon cancer

Evidence supports three-year interval for multi-target stool DNA screening for those at average risk of colon cancer

by Regenstrief InstituteCredit: Unsplash/CC0 Public DomainA scientific study exploring the appropriate interval for colorectal cancer screening via non-invasive multi-target stool DNA testing for
Oncology February 03,2024
Evidence supports three-year interval for multi-target stool DNA screening for those at average risk of colon cancer

Evidence supports three-year interval for multi-target stool DNA screening for those at average risk of colon cancer

by Regenstrief InstituteCredit: Unsplash/CC0 Public DomainA scientific study exploring the appropriate interval for colorectal cancer screening via non-invasive multi-target stool DNA testing for
Oncology February 03,2024
A brief cognitive behavioral therapy appears promising for head and neck cancer survivors

A brief cognitive behavioral therapy appears promising for head and neck cancer survivors

by Medical University of South CarolinaA microvascular reconstructive surgeon by training, Dr. Evan Graboyes became interested in alleviating body-image distress when he saw how much his head and
Oncology February 03,2024
A brief cognitive behavioral therapy appears promising for head and neck cancer survivors

A brief cognitive behavioral therapy appears promising for head and neck cancer survivors

by Medical University of South CarolinaA microvascular reconstructive surgeon by training, Dr. Evan Graboyes became interested in alleviating body-image distress when he saw how much his head and
Oncology February 03,2024
Some young cancer survivors face higher risk of premature heart failure

Some young cancer survivors face higher risk of premature heart failure

by Northwestern UniversityIncident Heart Failure Among YA Cancer Survivors (A) Comparison of history of anthracycline treatment vs none. (B) Stratified by young adult (YA) cancers commonly treate
Oncology February 03,2024
Some young cancer survivors face higher risk of premature heart failure

Some young cancer survivors face higher risk of premature heart failure

by Northwestern UniversityIncident Heart Failure Among YA Cancer Survivors (A) Comparison of history of anthracycline treatment vs none. (B) Stratified by young adult (YA) cancers commonly treate
Oncology February 03,2024
Proton radiotherapy treats esophageal cancer for first time in Switzerland

Proton radiotherapy treats esophageal cancer for first time in Switzerland

by Paul Scherrer InstituteGantry 3 at the Center for Proton Therapy at PSI. With the help of this rotating treatment apparatus, cancer patients are irradiated with protons to destroy tumours. Cre
Oncology February 03,2024
Proton radiotherapy treats esophageal cancer for first time in Switzerland

Proton radiotherapy treats esophageal cancer for first time in Switzerland

by Paul Scherrer InstituteGantry 3 at the Center for Proton Therapy at PSI. With the help of this rotating treatment apparatus, cancer patients are irradiated with protons to destroy tumours. Cre
Oncology February 03,2024
Study: Involving hospitalists in inpatient cancer care reduces patient stays, oncologist stress

Study: Involving hospitalists in inpatient cancer care reduces patient stays, oncologist stress

by Yale UniversityCredit: CC0 Public DomainInvolving hospitalists in the co-management of care for patients with cancer is associated with decreased length of hospital stay for patients, increase
Oncology February 03,2024
Study: Involving hospitalists in inpatient cancer care reduces patient stays, oncologist stress

Study: Involving hospitalists in inpatient cancer care reduces patient stays, oncologist stress

by Yale UniversityCredit: CC0 Public DomainInvolving hospitalists in the co-management of care for patients with cancer is associated with decreased length of hospital stay for patients, increase
Oncology February 03,2024
Researchers develop tool to measure patient health and well-being after radionuclide therapy

Researchers develop tool to measure patient health and well-being after radionuclide therapy

by H. Lee Moffitt Cancer Center & Research InstituteGraphical abstract. Credit:Journal of Nuclear Medicine(2023). DOI: 10.2967/jnumed.122.264946Cancer is a devasting disease that
Oncology February 03,2024
Researchers develop tool to measure patient health and well-being after radionuclide therapy

Researchers develop tool to measure patient health and well-being after radionuclide therapy

by H. Lee Moffitt Cancer Center & Research InstituteGraphical abstract. Credit:Journal of Nuclear Medicine(2023). DOI: 10.2967/jnumed.122.264946Cancer is a devasting disease that
Oncology February 03,2024
Investigational deep learning model may help stratify risk for patients with endometrial cancer

Investigational deep learning model may help stratify risk for patients with endometrial cancer

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainAn investigational deep learning model requiring one histopathologic slide accurately predicted the risk of distant rec
Oncology February 03,2024
Investigational deep learning model may help stratify risk for patients with endometrial cancer

Investigational deep learning model may help stratify risk for patients with endometrial cancer

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainAn investigational deep learning model requiring one histopathologic slide accurately predicted the risk of distant rec
Oncology February 03,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com